Where did Dr. Meghana Prabhu S complete her DM in Therapeutic Nuclear Medicine?

Dr. Meghana Prabhu S completed her DM in Therapeutic Nuclear Medicine at the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi.

What are some of Dr. Meghana Prabhu S's research accomplishments?

Dr. Meghana Prabhu S has over 24 publications, has authored book chapters, and serves as a reviewer for international medical journals.

What specific conditions does Dr. Meghana Prabhu S treat using nuclear medicine techniques?

Dr. Meghana Prabhu S uses nuclear medicine techniques to address conditions such as prostate cancer, neuroendocrine cancer, thyroid cancer, and Pheochromocytoma / Paraganglioma.

What are Dr. Meghana Prabhu S's academic qualifications?

Dr. Meghana Prabhu S holds an MBBS, DNB in Nuclear Medicine, and a DM in Therapeutic Nuclear Medicine from AIIMS, New Delhi. She is also a Fellow of the Asian Nuclear Medicine Board (FANMB).

What is Dr. Meghana Prabhu S's experience in the field of Nuclear Medicine?

Dr. Meghana Prabhu S previously held the role of Assistant Professor in Nuclear Medicine at ILBS, New Delhi, from 2020 to 2022.

Is Dr. Meghana Prabhu S a member of any professional organizations?

Dr. Meghana Prabhu S is a Fellow of the Asian Nuclear Medicine Board (FANMB).

What are some of the treatments offered by Dr. Meghana Prabhu S?

Dr. Meghana Prabhu S offers treatments such as General Nuclear Medicine Imaging, PET – CT imaging, Nuclear Oncology, Theranostics related to Prostate Cancer, Neuroendocrine Cancer, Thyroid Cancer, Pheochromocytoma / Paraganglioma, SIRT, and Targeted Alpha Therapeutics.

What are some of Dr. Meghana Prabhu S's areas of expertise?

Dr. Meghana Prabhu S is an expert in Nuclear Oncology and Theranostics in Nuclear Medicine, with a focus on applying these techniques to address various cancer types.

How does Dr. Meghana Prabhu S contribute to the advancement of medical understanding?

Dr. Meghana Prabhu S actively participates in medical conferences and Continuing Medical Education (CME) events, presenting papers to advance medical understanding and practice.

Dr. Meghana Prabhu S

Consultant (Nuclear Medicine)

Consults at:

Amrita Hospital Faridabad

5.0

Surgeries

N/A

Experience

6+ years

Get A Consultation

About

Dr. Meghana Prabhu S is a distinguished medical professional with specialized training in Therapeutic Nuclear Medicine.
She is part of a select group of doctors in the country with a DM degree in Therapeutic Nuclear Medicine, a program she completed at the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi.
Dr. Prabhu is deeply engaged in research activities, boasting an impressive portfolio of over 24 publications in addition to authoring book chapters.
Her research endeavors have led her to serve as a reviewer for various international medical journals, contributing her insights to the advancement of medical knowledge.
Nuclear Oncology and Theranostics in Nuclear Medicine are areas of keen interest for Dr. Prabhu, and she specializes in applying these techniques to address conditions such as prostate cancer, neuroendocrine cancer, thyroid cancer, and targeted alpha therapy.
Her extensive academic background includes medical degrees such as MBBS, DNB in Nuclear Medicine, and a DM in Therapeutic Nuclear Medicine from AIIMS, New Delhi.
She is also a Fellow of the Asian Nuclear Medicine Board (FANMB), reflecting her commitment to excellence and recognition within her field.
Dr. Meghana Prabhu S has previously held the role of Assistant Professor in Nuclear Medicine at ILBS, New Delhi, from 2020 to 2022.
Her active participation in medical conferences and Continuing Medical Education (CME) events is evident through her presentation of several papers, showcasing her dedication to advancing medical understanding and practice.

Specializations & Treatments:

General Nuclear Medicine Imaging
PET – CT imaging, Nuclear Oncology
Theranostics related to Prostate Cancer, Neuroendocrine Cancer, Thyroid Cancer, Pheochromocytoma / Paraganglioma; SIRT, Targeted Alpha Therapeutics.